Abstract
The new technology available for vaccine development allows clinicians to administer vaccines to treat chronic diseases, such as dementia and high blood pressure. A vaccine for Alzheimer’s disease targeting the amyloid β and tau proteins and a high blood pressure vaccine targeting the renin-angiotensin system have been developed and advanced to clinical trials. When these vaccines are established in the future as therapeutic options for chronic diseases, their administration several times a year will replace a daily medication. Since social security expenses have increased along with social problems in our country, which has seen rapid increases in the aging population, these vaccines may provide cost benefits. Furthermore, improvements in medicine adherence might be achieved as a clinical merit of the vaccine treatment for chronic diseases. Because the number of aging patients using multiple drugs (polypharmacy) has increased, the management of administered drugs requires extensive human resources. If a vaccine for chronic diseases can decrease the number of drugs taken by patients, it will contribute to improvements in social problems. Moreover, an anti-inflammatory cytokine vaccine has been developed for chronic inflammatory diseases, which will be able to replace antibody therapy in the future.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ambühl PM, Tissot AC, Fulurija A et al (2007) A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 25:63–72
Biton J, Semerano L, Delavallée L et al (2011) Interplay between TNF and regulatory T cells in a TNF-driven murine model of arthritis. J Immunol 186:3899–3910. https://doi.org/10.4049/jimmunol.1003372
Brown MJ, Coltart J, Gunewardena K et al (2004) Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 107:167–173
Delavallée L, Le Buanec H, Bessis N et al (2008) Early and long-lasting protection from arthritis in tumour necrosis factor alpha (TNFalpha) transgenic mice vaccinated against TNFalpha. Ann Rheum Dis 67:1332–1338. https://doi.org/10.1136/ard.2007.079137
Delavallée L, Semerano L, Assier E et al (2009) Active immunization to tumor necrosis factor-alpha is effective in treating chronic established inflammatory disease: a long-term study in a transgenic model of arthritis. Arthritis Res Ther 11:R195. https://doi.org/10.1186/ar2897
Downham MR, Auton TR, Rosul A et al (2003) Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. Br J Clin Pharmacol 56:505–512
Durez P, Vandepapeliere P, Miranda P et al (2014) Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trial. PLoS One 9(12):e113465. https://doi.org/10.1371/journal.pone.0113465
Gardiner SM, Auton TR, Downham MR et al (2000) Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br J Pharmacol 129:1178–1182
Harris JR, Markl J (1999) Keyhole limpet hemocyanin (KLH): a biomedical review. Micron.30:597–623
Hayward MD, Jones BK, Saparov A et al (2007) An extensive phenotypic characterization of the hTNFalpha transgenic mice. BMC Physiol 7:13. https://doi.org/10.1186/1472-6793-7-13
Helmer OM (1958) Studies on renin antibodies. Circulation 17:648–652
Julius S, Nesbitt SD, Egan BM et al (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–1697
Koriyama H, Nakagami H, Nakagami F et al (2015) Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats. Hypertension 66:167–174. https://doi.org/10.1161/HYPERTENSIONAHA.114.04534
Le Buanec H, Delavallée L, Bessis N et al (2006) TNFalpha kinoid vaccination-induced neutralizing antibodies to TNFalpha protect mice from autologous TNFalpha-driven chronic and acute inflammation. Proc Natl Acad Sci U S A 103:19442–19447. https://doi.org/10.1073/pnas.0604827103
Michel JB, Guettier C, Philippe M et al (1987) Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci U S A 84:4346–4350
Michel JB, Sayah S, Guettier C et al (1990) Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 81:1899–1910
Nakagami F, Koriyama H, Nakagami H et al (2013) Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. PLoS One 8:e60493. https://doi.org/10.1371/journal.pone.0060493
Nakaya H, Sasamura H, Hayashi M, Saruta T (2001) Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis. J Am Soc Nephrol 12(4):659–666
Semerano L, Assier E, Delavallée L, Boissier M-C (2011) Kinoid of human tumor necrosis factor-alpha for rheumatoid arthritis. Expert Opin Biol Ther 11:545–550. https://doi.org/10.1517/14712598.2011.566856
Tissot AC, Maurer P, Nussberger J et al (2008) Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371:821–827
Wakayama K, Shimamura M, Suzuki JI et al (2017) Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress. Stroke 48:1362–1368
Wakerlin GE (1958) Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. Circulation 17:653–657
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Nakagami, H., Morishita, R. (2019). Closing: Clinical Applications of Therapeutic Vaccines in the Near Future. In: Nakagami, H. (eds) Therapeutic Vaccines as Novel Immunotherapy. Springer, Singapore. https://doi.org/10.1007/978-981-32-9628-2_8
Download citation
DOI: https://doi.org/10.1007/978-981-32-9628-2_8
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-32-9627-5
Online ISBN: 978-981-32-9628-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)